Risk of HAART therapy in hepatitis C [1]

Hepatology

Volumn 35, Issue 3, 2002, Pages 730-

  McGovern, Barbara ^a   Bica, Ioana ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; HYDROXYUREA; RECOMBINANT ALPHA2B INTERFERON; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LACTIC ACIDOSIS; LETTER; OUTCOMES RESEARCH; PANCREATITIS; PRIORITY JOURNAL;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG INTERACTIONS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; RIBAVIRIN; RISK;

EID: 0036192282     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.32094     Document Type: Letter

References (11)

1. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders
2. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection
3. Mitochondrial toxic effects and ribavirin
4. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: A looming obstacle for long-term antiretroviral therapy?
5. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity
6. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs
7. Mechanism of the potentiating effect of ribavirin on the activity of 2′,3′-dideoxyinosine against human immunodeficiency virus
8. Selective depletion of DNA precursors
9. Combination therapy with didanosine and interferon-alpha in human immunodeficiency virus-infected patients: Results of a phase I/II trial
10. Hyperlactatemia and antiretroviral therapy: The Swiss HIV cohort study